Biosimiliars, which are similar in chemical makeup to branded drugs, are lower cost alternatives which experts believe could heavily impact the market in coming years. In the US, the FDA just approved the first biosimilar, a Novartis drug to increase the white blood cell count. In Europe, biosimilars have been legal since 2006. Biosimiliars are posed to compete with blockbuster drugs as their patents expire, driving down prices and making treatment more accessible to patients. Generic drug makers often face litigation when preparing to start research on a new drug before the branded patent expires. It is expected that biosimilar drugs will face some of the same litigation issues.